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Abstract 
Background: Fewer circulating endothelial progenitor cells (EPCs) and increased plasma (C-term) stromal cell-
derived factor 1α (SDF-1α), a substrate of DPP-4, are biomarkers, and perhaps mediators, of cardiovascular risk and 
mortality. Short-term/acute treatment with DPP-4 inhibitors improve EPC bioavailability; however, long-term effects of 
DPP-4i on EPCs bioavailability/plasma (C-term) SDF-1α are unknown.
Methods: Randomized (2:1) open-label trial to compare the effects of vildagliptin (V) (100 mg/day) vs glibencla-
mide (G) (2.5 mg bid to a maximal dose of 5 mg bid) on circulating EPC levels at 4 and 12 months of treatment in 64 
patients with type 2 diabetes in metformin failure. At baseline, and after 4 and 12 months, main clinical/biohumoral 
parameters, inflammatory biomarkers, concomitant therapies, EPC number (CD34+/CD133+/KDR+/106 cytometric 
events) and plasma (C-term) SDF-1α (R&D system) were assessed.
Results: Baseline characteristics were comparable in the two groups. V and G similarly and significantly (p < 0.0001) 
improved glucose control. At 12 months, V significantly increased EPC number (p < 0.05) and significantly reduced 
(C-term) SDF-1α plasma levels (p < 0.01) compared to G, with no differences in inflammatory biomarkers.
Conclusions: V exerts a long-term favorable effect on EPC and (C-term) SDF-1α levels at glucose equipoise, thereby 
implying a putative beneficial effect on vascular integrity.
Trial registration Clinical Trials number: NCT01822548; name: Effect of Vildagliptin vs. Glibenclamide on Circulating 
Endothelial Progenitor Cell Number Type 2 Diabetes. Registered 28 March, 2013
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Background
Endothelial progenitor cells (EPCs) are key players in 
the process of endothelial repair/replacement as they 
substantially contribute to endothelial homeostasis and 
neoangiogenesis in response to different detrimental 
cues [1]. In type 2 diabetes, EPC number is reduced, 
presumably resulting in an unbalance between the pro-
cesses of endothelial injury and repair [2]. Fewer EPCs 
are a biomarker, and perhaps a pathogenetic factor, 
of vascular damage also in diabetes and the presence 
of diabetic macrovascular complications is associ-
ated with a further reduction in circulating EPC num-
ber [3]. Importantly, lower EPC number has been also 
shown to predict incident cardiovascular (CV) disease 
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[4] and death [5]. Based on the previous considerations, 
anti-diabetic drugs effective in enhancing EPC number 
may convey an added value, beyond glucose control, to 
reduce CV risk and to prevent CV disease in patients 
with type 2 diabetes. A number of anti-diabetic drugs, 
namely pioglitazone [6] and insulin [7], and statins [8] 
have been shown to improve EPC biology in ex  vivo 
studies. Recent evidence points to a potential role of 
dipeptidyl peptidase-4 inhibitors (DPP-4i) in increas-
ing circulating EPC number. Short-term treatment 
(4  weeks) with sitagliptin in a small non-randomised 
trial [9] and acute treatment (4  days) with linagliptin 
improved EPC bioavailability [10]. A subsequent study 
investigated the mid-term effects of sitagliptin in boost-
ing EPC levels, but the reported results may be poten-
tially attributable to a regression to the mean effect [11]. 
Long-term effects of DPP-4i—and specifically of the 
DPP-4i vildagliptin—in enhancing EPCs bioavailability 
are unknown.
Importantly, DPP-4 is a ubiquitously expressed pro-
tein which cleaves NH2-terminal dipeptides from vari-
ous proteins. One relevant DPP-4 substrate, besides 
glucagon-like peptide-1 (GLP-1), is stromal cell-
derived factor 1α (SDF-1α). SDF-1∝ may act as a dou-
ble edge sword with respect to the CV system [12]. 
On the one hand, it is a potent chemokine stimulating 
stem cell mobilization, including EPC, from the bone 
marrow and, it plays a positive role in the angiogenic 
process following acute ischemic injury [13]. On the 
other hand, C-terminal (C-term) SDF-1α has recently 
emerged as a robust biomarker of CV diseases and 
mortality. In the Framingham Heart Study, higher 
(C-term) SDF-1α levels were associated with the pres-
ence of several CV risk factors and independently 
with heart failure and with 10 year all-cause mortality 
[14]. In the chronic renal insufficiency cohort higher 
(C-term) SDF-1∝ levels predicted increased 6-year 
mortality [15].
The present investigation, therefore, was undertaken 
to compare long-term effects of the DPP-4i (vildaglip-
tin) vs sulfonylurea (glibenclamide) (to achieve glycaemic 
equipoise) in patients with type 2 diabetes on a. the bio-
availability of EPCs as key regulators of endothelial repair 
processes b. plasma levels of (C-term) SDF-1α as a bio-
marker of CV risk and mortality.
Methods
We conducted a randomized (2:1), open-label active-
treatment-controlled clinical trial (NCT01822548) to 
compare the effects of vildagliptin (V) (100 mg/daily) vs 
glibenclamide (G) (2.5 mg bid to a maximal dose of 5 mg 
bid) on circulating EPC and (C-term) SDF-1∝ levels at 4 
and 12 months of treatment.
Subjects
Individuals with type 2 diabetes were recruited in the 
outpatient Diabetes Unit of Parma University Hospital 
among those participating in a study funded by the Ital-
ian Research program Regione-Università 2007–2009. 
Eligible subjects were men and women aged ≥35 years, 
with an established diagnosis of type 2 diabetes (ADA cri-
teria) [16], with at least 1 year of disease duration at the 
time of the screening visit, in metformin failure [HBA1C 
7–9%; 53–75  mmol/mol] and BMI ≥  20 or ≤40  kg/m2. 
Other inclusion criteria were: treatment with metformin 
in monotherapy at a stable dose of at least 1.5 g/day (or 
maximum tolerated dose) in the 3  months prior to the 
screening visit. Key exclusion criteria included type 1 or 
secondary diabetes, significant progression of diabetic 
macro- (acute cerebro-vascular event or any revascu-
larization procedure, clinically-relevant peripheral artery 
disease, onset of a diabetic foot) or micro- (retinopa-
thy progression, increase of at least 0.5 mg/dl of plasma 
creatinine or progression to macro-proteinuria, onset 
of clinically-relevant neuropathy) angiopathy in the 6 
months prior to study visit. Other exclusion criteria 
included history of acute or chronic pancreatitis, pancre-
atectomy, gastric surgery, inflammatory bowel disease, 
organ failure or other severe diseases limiting life expec-
tancy; drugs interfering with glucose levels (i.e. corticos-
teroids) or acute diseases (i.e. infections) in the 3 months 
before screening visit, history of inflammatory/infective/
autoimmune chronic disease, contraindications to the 
maintenance of the background therapy (metformin), 
including—but not limited to—chronic kidney failure 
or plasma creatinine concentrations  >1.5  mg/dl, severe 
respiratory failure, etc.; contraindications to the use of a 
sulfonylurea or DPP-4 inhibitors, clinically-relevant psy-
chiatric disorders, any clinically significant abnormal-
ity identified in physical examination, laboratory tests 
(known chronic liver diseases, including HBV and HCV 
infection; liver markers above 2 times the upper normal 
limit) or vital signs at screening, and pregnancy.
Study design
Eligible subjects were randomized in a 2:1 ratio to receive 
either V 100  mg/daily (50  mg bid) or G for 12  months. 
Treatment allocation and titration regimens were not 
blinded. Randomization was based on random num-
bers generated by a statistical software. Randomization 
numbers and sequence were kept by the data manager. 
Randomization list was concealed to study investiga-
tors. Principal investigator and collaborators investiga-
tor enrolled the participants. Drug treatment with G was 
started with 2.5 mg bid (daily total = 5 mg) 30 min before 
breakfast and dinner. After 1  month, G dose was up-
titrated to a maximum of 7.5 mg/day and at month 4 up 
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to a maximum of 5  mg bid to achieve pre-prandial fin-
ger-stick glucose values between 80 and 140 mg/dl (4.4–
7.8 mmol/l) and post-prandial ≤200 mg/dl (11 mmol/l). 
No dose titration was planned for V. At baseline, medi-
cal history, current therapies, personal history of diabe-
tes and CV disease, smoking and drinking habits were 
recorded. During the treatment period, subjects returned 
to the clinic for efficacy and safety assessments at 4 and 
12 months. At baseline and at each following visit clini-
cal parameters (BMI and systolic and diastolic blood 
pressure) and blood test [fasting plasma glucose, (FPG) 
HBA1C, plasma C-peptide, total cholesterol, triglycer-
ides, HDL-cholesterol, liver enzymes, serum creatinine 
and uric acid] were performed. Estimated eGFR was cal-
culated with the CKD-EPI formula [17]. In addition, cir-
culating pro-inflammatory chemokine/cytokine profile 
[C-reactive protein (CRP), IL-6, TNF-∝], brain natriu-
retic peptide (BNP), total GLP-1, (C-term) SDF-1∝ and 
EPC number were also assessed. The study was con-
ducted according to the guidelines of good clinical prac-
tice and the Declaration of Helsinki. The protocol and 
amendments were approved by the Parma Ethics Com-
mittee. All subjects provided written informed consent 
prior to study entry.
Quantification of circulating endothelial progenitor cells
Circulating EPCs were assessed by cytofluorimetric 
analysis for the expression of CD34, CD133, and kinase 
insert domain receptor (KDR) surface antigens: as previ-
ously described in detail [18–20]. Briefly, fasting blood 
samples were collected in EDTA and stained within 2 h 
with 10 μl fluorescein isothiocyanate (FITC)-conjugated 
anti-human CD34 monoclonal antibody (mAb) (Bec-
ton–Dickinson Biosciences, Franklin Lakes, NJ, USA), 
20  μl allophycocyanin (APC)-conjugated anti-human 
CD133 mAb (Miltenyi Biotec, CA, San Diego, U.S.) 20 μl 
phycoerythrin (PE)-conjugated anti-human KDR mAb 
(R&D Systems, Minneapolis, MN, USA) and 20 μl peri-
dinin chlorophyll protein complex (PerCP)-conjugated 
CXCR-4 (R&D Systems). Immunoglobulins were used 
as isotype controls (BD Biosciences). CD34+/CD133+/
KDR+ cells were identified by evaluating the expression 
of KDR within the CD133+/CD34+ cells in the lympho-
monocyte population (Fig. 1). The percentage of CD34+/
CD133+/KDR+ cells co-expressing CXCR-4 was also 
assessed. Circulating EPCs (expressed as number of 
CD133+/CD34+/KDR+ cells/106 total cytofluorimetric 
events) were acquired in a FACSCantoII cytometer and 
analysed using FACSDiva software (both by BD Bio-
sciences). A single trained operator performed all cyto-
fluorimetric analyses and was blinded to the patients’ 
status and allocation.
(C‑term) SDF‑1α, IL‑6, TNF α, CRP, BNP and total GLP‑1 
assessment
ELISA kits were used to measure plasma levels of 
(C-term) SDF-1α (Human CXCL12/SDF-1 alpha Quan-
tikine ELISA Kit by R&D system), IL-6 (Human IL-6 
ELISA Pro Kit by Mabtech, Nacka Strand, Sweden) and 
TNF-α (TNF alpha Ultrasensitive ELISA Kit, Thermo 
Fisher Scientific, Waltham, MA U.S.A.) following manu-
facturer’s instruction. Intra- and inter-assay coefficients 
of variation were 3.5 and 10.6% for SDF-1α, 2.5 and 
3.8% for IL-6 and 6.0 and 8.5% for TNF-α, respectively. 
Cytokine/chemokine concentrations were calculated in 
duplicate by using a standard curve generated by seri-
ally diluting reconstituted standards and by measuring 
the absorbance at 450 nm in a microplate reader (Multis-
kan™ FC Microplate Photometer, Thermo Scientific).
Serum levels of extended range C-reactive protein were 
determined using the particle-enhanced turbidimetric 
immunoassay (PETIA technique; Siemens Dimension, 
USA). The reference range in this method is 0.0–5.0 mg/l. 
BNP levels were assessed using an Alere Triage reagent 
pack (Alere Inc., Ottawa, ON, CAN) and analysed in an 
automated D ×  I 800 immunoanalyzer (Beckman-Coul-
ter, Fullerton, CA, USA).
Total GLP-1 was measured by a magnetic bead kit 
(Merck-Millipore, Vimodrone, Italy) according to kit 
instructions and analyzed on a MagPix (Luminex Corpo-
ration). The assay is based on the attachment of GLP-1 to 
magnetic beads and processing using LED excitation.
Study endpoints
The study primary endpoint was the change from base-
line values of the EPC number in the V vs G arm at 4 and 
12 months. The secondary endpoint was the change from 
baseline values of the (C-term) SDF-1∝ levels in the V vs 
G arm at 4 and 12 months. Safety assessments included 
adverse events (AEs), incidence and severity of hypogly-
cemia [21], discontinuation for hyperglycemia (defined as 
HBA1C ≥ 8%; ≥63.9 mmol/mol) at 4 month, use of res-
cue medication for hyperglycemia, abnormal findings in 
physical exam and laboratory workup.
Sample size determination
Sample size was calculated to achieve 80% power to reject 
the null hypothesis of equal mean changes in the primary 
endpoint when the population mean difference is 0.15 
with a standard deviation of 0.2 in both groups and with 
a significance level (∝) of 0.05 using a two-sided two-
sample equal-variance t test (difference between the two 
treatments at 12 months) (software PASS- NCSS, USA). 
In addition, 40 subjects were sufficient to guarantee a 
delta value between 0 and 12  months in the treatment 
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group of  ~10% (SD of pair differences 20%) with a ∝ 
value of 5% and β = 80% [22].
Statistical analysis
Continuous variables are expressed as mean ± standard 
deviation or median (interquartile range IQR) for skewed 
distributed data. Categorical variables are expressed as 
frequencies. EPC values were log-transformed in order 
to achieve normal distribution as confirmed by Kolmogo-
rov–Smirnov test. Comparisons of parameters at baseline 
between treatment groups were performed using the t 
test for normally distributed data, the Mann–Whitney 
test for non-normally distributed variables otherwise and 
the Chi square test for categorical variables.
Intra-groups differences within variables before 
and after treatment during the study have been ana-
lysed using a general linear model (GLM) for repeated 
measures with treatment (V vs G) and time (baseline and 
visits at 4 and 12 months) as main factors. Primary (EPC) 
and secondary (SDF-1α) endpoint analyses were per-
formed by means of GLM with adjustment for baseline 
levels. Analysis was conducted according to the intention 
to treat (ITT) approach. A p value ≤0.05 was considered 
significant. Statistical analysis was performed using SPSS 
v. 22 (IBM Statistics).
Results
Study subjects
Seventy-three individuals with type 2 diabetes 
entered the screening phase. Patient were screened 
and enrolled between September 2010 and December 
2013 (last patient follow-up at 12  months in Decem-
ber 2014). Of these, 64 were randomised: 40 in the 
V arm and 24 in the G arm according to 2:1 ratio 
Fig. 1 EPC number evaluation. Flow-cytometry analysis scatter plots to assess EPC number. Within the lymphomonocyte population (a) CD34 (b) 
and CD133 (c) positive cells were gated and evaluated for the expression of KDR to identify CD34+/CD133+/KDR+ cells (d)
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randomisation. Two subjects randomised to the V arm 
did not start the trial drug due to lack of compliance. 
None of the other subjects in the V arm discontinued 
the intervention in the 12  month follow-up, whereas 
in five subjects in the G arm the comparator drug was 
discontinued on the basis of the clinical judgment of 
their physician, owing to hypoglycemic (4 mild and 1 
severe) events. The median duration of therapy was 
12 (IQR 11–13) months without significant difference 
between study arms [12 (11–12) for V, 12 (7–13) for G]. 
Figure 2 shows the CONSORT flow chart according to 
ITT analysis. As expected by the randomisation proce-
dure, baseline characteristics, concomitant therapies 
and metformin doses (mg/day) were similar in the two 
groups as shown in Table 1.
Effect of treatment on clinical parameters
As expected, both therapies significantly (GLM 
p  <  0.0001) and similarly (p  =  0.92) improved glu-
cose control during the 12-months follow-up (Table  2). 
Accordingly, FPG was significantly and similarly reduced 
during the follow-up in both arms (p < 0.0001). Thus, glu-
cose equipoise between the two study arms was achieved.
A small, albeit statistically significant, decrease in 
eGFR (p  <  0.05) occurred during the follow-up in both 
study arms. No significant differences in other study 
Analysed for primary end-point (n=40)
Discontinued intervention (n=0)
Allocated to Vildagliptin (n=40)
-Received allocated intervention (n=38)
-Did not receive allocated intervention (only 
metformin) (n=2)
Discontinued intervention (n=5)
Allocated to Glibenclamide (n=24)
¨ Received allocated intervention (n=24)








Fig. 2 Consort flow chart. The figure shows the consort flow chart according to ITT analysis
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parameters (i.e. BMI and lipid profile) with respect to 
treatment and time were observed (Table 2).
Effect of treatment on primary and secondary endpoints
EPCs and (C-term) SDF-1α levels in the two arms during 
the study and both time and treatment effects -and their 
interaction- according to the GLM model are shown in 
Table  2. Vildagliptin treatment significantly increased 
EPC number at 12  months (p  =  0.034; β  =  0.362; SE 
0.166) compared to glibenclamide after adjusting for 
baseline EPC values as shown in Fig.  3a (GLM model). 
No significant between-arm difference in EPC count was 
found at 4 months (p =  0.196; β =  0.236; SE 0.180). At 
baseline EPC were 91.2% (V) and 95.9% (G) positive for 
CXCR-4 expression, with no between-arm significant 
differences at 4 and 12  months. Vildagliptin treatment 
significantly reduced (C-term) SDF-1α plasma levels at 
4 (p =  0.004; β = −0.102; SE =  0.034) and 12  months 
(p < 0.001; β = −0.185; SE = 0.043) compared to the G 
arm after adjustment for baseline values (GLM) (Fig. 3b).
Other assays
IL-6, TNF-α and CRP plasma levels were stable through-
out the study in both groups. BNP slightly and equally 
increased in both study arms (p  <  0.05) (Table  2). No 
differences in total GLP-1 plasma levels were observed 
before and after treatment in both study arms (Table 2).
Adverse events
Five out of 24 (21%) patients in the G arm experienced 
hypoglycaemia: mild hypoglycemic events (n  =  4) and 
severe hypoglycemic (n = 1) event occurred at month 1 
(0.5–2.5) after randomisation. These events led to treat-
ment discontinuation. No adverse events were reported 
in the V arm during the whole study period.
Discussion
Our findings show that vildagliptin, but not glibencla-
mide, exerts a beneficial long-term (12-month) effect on 
circulating EPC levels at glucose equipoise in individuals 
with type 2 diabetes. Since a reduced EPC number is a 
Table 1 Subject characteristics
Baseline characteristics of the study subjects expressed as (mean ± SD) or median (IQR) for continuous data and n (%) for categorical data
Variables Missing Total (N = 64) Vildagliptin (N = 40) Glibenclamide (N = 24) p
Age (years) 0 62 ± 9 61 ± 9 63 ± 10 0.28
Gender male n (%) 0 43 (67) 26 (65) 17 (71) 0.63
Smoking habit n (%) 3 13 (22) 7 (19) 6 (26) 0.72
CVD history n (%) 2 13 (20) 8 (20) 5 (21) 0.94
Hypertension n (%) 2 43 (67) 25 (63) 18 (75) 0.40
Disease duration (yrs) 0 6.5 (3–10) 7 (4–11) 5 (1–10) 0.30
Plasma glucose (mg/dl) 0 154 ± 34 155 ± 36 150 ± 30 0.67
HBA1C (%) 0 7.7 (7.4–8.1) 7.7 (7.4–7.9) 7.7 (7.5–8.1) 0.57
HBA1C (mmol/mol) 0 61 (57–65) 61 (57–64) 61 (58–65) 0.57
Plasma C-peptide (ng/ml) 8 2.67 (2.16–3.52) 2.66 (2.07–3.48) 2.78 (2.21–4.34) 0.69
BMI (kg/m2) 0 29.0 (26.2–33.9) 29.1 (26.8–32.9) 28.9 (25.4–34.1) 0.94
Serum creatinine (mg/dl) 2 0.8 (0.6–0.9) 0.8 (0.6–0.9) 0.8 (0.6–1.0) 1.0
GFR (CKD-EPI) (ml/min/1.73 m2) 3 96.0 ± 12.7 96.1 ± 11.8 96.0 ± 14.5 0.77
Total cholesterol (mg/dl) 2 166.6 ± 30.3 168.5 ± 31.1 163.2 ± 29.8 0.56
HDL-cholesterol (mg/dl) 2 45 (40–54) 45 (41–51) 45 (37–55) 0.82
Tryglicerides (mg/ml) 2 111 (71–155) 100 (68–140) 117 (78–1182) 0.48
GGT (U/l) 4 20 (16–32) 19 (16–30) 23 (14–36) 0.63
AST (U/l) 4 23 (19–28) 23 (18–27) 23 (19–28) 0.89
ALT (U/l) 4 27 (19–38) 27 (19–38) 28 (20–39) 0.63
Uric acid (mg/dl) 4 5.2 (4.5–6.0) 5.2 (4.5–5.9) 5.2 (4.4–6.3) 0.76
EPC (n/106 events) 0 38.0 (24.2–58.2) 39.0 (24.0–58.2) 37.5 (25.0–59.8) 0.81
Therapies
 Anti-hypertensive n (%) 2 43 (67) 25 (64) 18 (75) 0.40
 Lipid-lowering n (%) 2 44 (69) 26 (67) 18 (75) 0.33
 Antiplatelet n (%) 2 30 (47) 20 (51) 10 (42) 0.40
 Metformin (mg/day) 0 2000 (1750–2735) 2000 (2000–2550) 2000 (1700–2400) 0.13
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Table 2 Results of GLM model
Data are reported as mean ± standard deviation or median (IQR)
Clinical variables, circulating markers and p values of GLM models (treatment, time and time × treatment effects)
GLM model for primary (EPC) and secondary (SDF-1α) endpoint was performed with adjustment for baseline levels
Statistically significant values (p < 0.05) are shown in italics
Vildagliptin Glibenclamide Treatment effect Time effect Interaction
HBA1C (%)
 Baseline 7.7 (7.4–7.9) 7.7 (7.5–8.1) p = 0.85 p < 0.001 p = 0.17
 4 months 6.8 (6.4–7.3) 6.8 (6.4–7.3)
 12 months 7.0 (6.5–7.3) 7.1 (6.5–7.5)
FPG (mg/dl)
 Baseline 155 ± 36 150 ± 30 p = 0.80 p < 0.001 p = 0.64
 4 months 130 ± 36 129 ± 28
 12 months 129 ± 28 129 ± 30
BMI (kg/m2)
 Baseline 29 (27–33) 29 (25–34) p = 0.80 p = 0.67 p = 0.79
 4 months 29 (26–33) 28 (26–33)
 12 months 24 (26–33) 29 (26–34)
eGFR (ml/min/1.73 m2)
 Baseline 96.1 ± 11.8 96.0 ± 14.5 p = 0.24 p = 0.039 p = 0.55
 4 months 95.8 ± 10.5 92.3 ± 14.7
 12 months 95.8 ± 12.0 92.5 ± 12.9
EPC (n/106 events)
 Baseline 39.0 (24.0–58.2) 37.5 (25–59.8) p = 0.025 p = 0.008 p = 0.58
 4 months 37.0 (27.0–65.0) 36.0 (23.0–54.2)
 12 months 45.0 (29.7–67) 32.0 (22.2–53.5)
Circulating markers
 SDF-1α (pg/ml)
  Baseline 2877 (2388–3713) 3134 (2763–4117) p < 0.001 p = 0.38 p = 0.035
  4 months 2293 (1585–3187) 3100 (2572–3782)
  12 months 2064 (1540–2954) 3336 (2778–3863)
 BNP (pg/ml)
  Baseline 3 (1–9) 3 (2–7) p = 0.41 p = 0.045 p = 0.71
  4 months 3 (1–8) 3 (1–5)
  12 months 5 (3–12) 6 (3–10)
 IL-6 (pg/ml)
  Baseline 4.7 (3.0–7.6) 6.1 (4.2–9.2) p = 0.93 p = 0.77 p = 0.15
  4 months 5.8 (3.7–9.7) 5.4 (3.5–8.2)
  12 months 5.0 (2.7–9.9) 5.4 (3.7–6.7)
 CRP (mg/l)
  Baseline 4.0 (3.2–5.7) 3.8 (2.6–6.3) p = 0.43 p = 0.51 p = 0.79
  4 months 4.0 (2.7–5.5) 3.2 (2.4–6.3)
  12 months 3.6 (2.3–6.1) 3.5 (2.9–3.9)
 TNFα (pg/ml)
  Baseline 1.4 (0.7–2.0) 1.6 (1.1–2.4) p = 0.24 p = 0.25 p = 0.97
  4 months 1.1 (0.5–1.8) 1.7 (1.3–2.4)
  12 months 1.1 (0.4–1.8) 1.4 (0.8–2.2)
 GLP-1 total (pM)
  Baseline 84.0 (66.2–109.0) 86.7 (73.7–97.0) p = 0.75 p = 0.83 p = 0.91
  4 months
  12 months 83.4 (68.8–107.0) 88.5 (75.5–114.6)
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biomarker and, perhaps, a pathogenetic factor of vascular 
disease, DPP-4 inhibition by vildagliptin may represent 
an attractive strategy to treat diabetes, beyond glucose 
control.
The effects of DPP-4i on EPC bioavailability were 
reported in short-term studies. The first evidence indi-
cated that a 4-week treatment with sitagliptin increased 
circulating EPC number (CD34+ and KDR+ cells) in 
a non-randomised study conducted in a small group 
of patients with type 2 diabetes [9]. The same authors 
reported the acute effects (4-days) of linagliptin admin-
istration in increasing circulating EPC number vs pla-
cebo in a group of individuals with type 2 diabetes, of 
whom 39% had concomitant chronic kidney disease 
(CKD) [10].
In a very recent paper, a mid-term (4-month) treatment 
with sitagliptin was associated with a significant increase 
in EPCs -phenotypically characterised as CD34+/CXCR-
4+ cells- in 30 patients with type 2 diabetes in poor glu-
cose control with metformin and/or sulphonylurea [11]. 
However, close scrutiny of the reported data raises the 
possibility that statistical significance might be also 
attributable to the effect of regression to the mean. In 
addition, in that study the improvement in glucose con-
trol was greater with sitagliptin compared to the com-
parator (glimepiride), thereby potentially implying that 
the effects of sitagliptin may be mediated by improved 
glucose control.
Indeed, glucose lowering per se can increase EPC bio-
availability [23, 24]. Thus, the long-term effect of DPP-4 
inhibition on systemic EPC bioavailability, independently 
of glucose control, remained somewhat uncertain.
Our study expands the hitherto findings in a larger ran-
domised-controlled long-term trial, with a DPP4-i—vild-
agliptin-, thus far unexplored as to these biologic effects. 
The results document a positive direct effect of vildaglip-
tin treatment on EPC bioavailability at glucose equipoise, 
definitely ruling out glucose control as a confounder. The 
effect of DPP-4 inhibition in raising EPC levels was sus-
tained for 12  months, strongly suggesting a long term 
beneficial effect of this therapy on the endothelial repair 
process and its counterbalancing role to endothelial 
injury.
These findings might partially explain the DPP-
4i-mediated beneficial vascular effects which have been 
reported in pre-clinical [25–27] and clinical studies [28, 
29].
However, it should be noticed that large intervention 
trials have failed to demonstrate any additional protec-
tive CV effect of this class of drugs compared to active 
comparators at glucose equipoise [30–32]. These trials 
have been conducted in high risk populations with dia-
betes, (∼80% with a history of CV disease in the saxaglip-
tin and cardiovascular outcomes in patients with type 2 
diabetes mellitus -SAVOR-TIMI-, with recent acute coro-
nary syndrome in the alogliptin after acute coronary syn-
drome in patients with type 2 diabetes -EXAMINE- and 
with established CV disease in the effect of sitagliptin 
on cardiovascular outcomes in type 2 diabetes -TECOS- 
studies), with diverse median follow-up durations (from 
19 months to 3 years). Long-term potential CV benefits 
in patients with type 2 diabetes at lower risk have not 
been investigated. It is possible, albeit not proved, that 
in patients in a less advanced stage of the natural history 
Fig. 3 Treatment effect. The figure displays the treatment effect (β-coefficient and SE) of vildagliptin (treating glibenclamide as reference group) on 
EPC number (a) and SDF-1α levels (b) in repeated measure GLM models after adjustment for baseline values. (*p < 0.05; **p < 0.01)
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of CV damage, such as those included in the present 
study, DPP-4 inhibition can provide protection against 
CV events. Noteworthy, the beneficial vascular effects 
of DPP-4i may be mirrored first by a microvascular 
improvement, subsequently leading to a long-term mac-
rovascular benefit [33, 34]. Accordingly, EPC levels pre-
dict microvascular outcomes in type 2 diabetes [35], 
suggesting that the DPP-4i-induced reduction in micro-
albuminuria progression [36] might be also mediated by 
an increase in EPC number; this hypothesis, although 
plausible, needs to be proven.
The chemokine SDF-1α is a substrate of DPP-4. Hence, 
DPP-4 inhibition might increase SDF-1α bioavailability, 
by restraining DPP-4-mediated degradation. However, 
SDF-1α is also emerging as a novel player among CV risk 
indicators/factors. SDF-1α is a pivotal mediator of stem 
cell mobilisation from the bone-marrow niches and of 
their homing to ischemic sites, promoting angiogenesis 
and vasculogenesis. This beneficial action is particularly 
relevant in experimental conditions of ischemia [37] or 
of injury-induced restenosis [38]. In humans, the results 
are controversial [39, 40]. In contrast, the role played by 
SDF-1α in atherogenesis/atherosclerosis might be differ-
ent. SDF-1α is released by the atherosclerotic plaques, 
it binds to its receptor which is expressed in inflamma-
tory cells (i.e. monocytes and macrophages), and it can 
promote chemotaxis, leukocyte recruitment and platelet 
aggregation [41], which result into accelerated plaque 
formation [42]. Furthermore, circulating (C-term) 
SDF-1α has emerged as an independent cardiovascular 
risk biomarker in large (>3000 individuals) prospective 
studies. In the Framingham Heart study, which included 
10% of individuals with diabetes, higher SDF-1α values 
were directly and independently associated with the risk 
of heart failure and 10-year all-cause mortality [14] and 
inversely with CD34+ (bone marrow-derived) circulating 
cell phenotypes. Consistently, higher SDF-1α levels inde-
pendently predicted incident myocardial infarction and 
death in a large cohort of high risk subjects with CKD 
(50% having diabetes) at 6-year follow-up [15].
Thus, the vildagliptin-induced reduction in plasma 
SDF-1α levels observed in this study should be inter-
preted in the context of the assessment of CV risk and 
not as a possible explanation of the DPP-4i mediated 
increase in EPC number.
Studies assessing SDF-1α in the course of treat-
ment with DPP-4i have reported either an increase or a 
decrease in the chemokine plasma levels [9–11]. These 
apparently discrepant findings of DPP-4 inhibition on 
circulating SDF1α levels can be due to methodological 
differences in SDF-1 assays. The assays used in our study, 
and in the epidemiological studies reporting a direct 
relationship between SDF-1α levels and CV risk, as is 
the above mentioned epidemiological studies [14, 15], 
are selective for the C-terminus of SDF-1α and meas-
ure total SDF-1α (active and non-active). In contrast, in 
those studies in which DPP-4 inhibition was reported 
to increase SDF-1 levels a custom assay specific for the 
N-terminus of SDF-1, which contains the active receptor 
(CXCR-4)-binding site and the X-Pro dipeptide cleaved 
by DPP-4, was used and only active SDF-1 was measured 
[9, 10]. While a role of the increase in the SDF-1α bioac-
tive form brought about by DPP-4 inhibition still needs 
to be firmly established, robust epidemiological evidence 
demonstrates that the total (C-term) form is indepen-
dently associated to incident CV disease and mortality. In 
analogy with the DPP-4/GLP-1 axis, we cannot exclude 
that a decrease in the total (C-term) SDF-1 with DDP-
4i may be paralleled by an increase in the bioactive form 
and vice versa [43].
Two additional findings of our study deserve to be 
commented.
BNP increased and eGFR decreased with no difference 
between study arms. It should be noted that in both cases 
the changes were so small as to be of questionable clini-
cal relevance, and could not be ascribed to vildagliptin 
treatment.
The putative mechanisms underlying DPP-4i ability to 
increase EPC bioavailability are beyond the scope of our 
study. However, the decrease in (C-term) SDF-1α plasma 
levels with DPP-4 inhibition, while it does not necessar-
ily negate a SDF-1α mediated mechanism, is not con-
sistent with it. DPP-4 inhibition is endowed with robust 
anti-inflammatory actions in cellular and mouse models 
which may explain the majority, if not all, of the pleio-
tropic effect of this class of drugs [44], possibly including 
the amelioration in EPC biology. However, data on DPP-
4i effect on plasma cytokine levels are scarce in humans 
[45] and the unchanged cytokine and CRP levels in our 
study seem not to support this hypothesis.
Strengths of our study include the controlled-ran-
domised study design, the relative large population 
involved, which has been extensively characterised, and, 
importantly, the 1-year follow-up, which ensures the 
demonstration of a durable DPP-4i effects on boost-
ing EPC bioavailability. In addition, our is the first evi-
dence of a beneficial effect on EPC caused by vildagliptin 
treatment.
Some limitations of our study should be recognized. 
Although we demonstrated that vildagliptin improves 
EPC bioavailability, the underlying pathophysiological 
explanation remains unclear and future studies are war-
ranted to unravel SDF-1α dependent and independent 
mechanisms. The clinical impact of the EPC and SDF-1α 
changes induced by vildagliptin, although concord-
antly pointing to a potential beneficial effect, remains 
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unknown. The open-label nature of the study also needs 
to be acknowledged.
In conclusion, vildagliptin exerts a beneficial long-
term effect on circulating EPC levels, at glucose equi-
poise, with a putative positive effect on vascular 
integrity. The vildagliptin-induced reduction in plasma 
SDF-1α levels might be desirable in light of the emerg-
ing role of circulating SDF-1α as an independent car-
diovascular risk biomarker.
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